Showing 1 - 2 of 2 results
Bristol-Myers Squibb developed BMS-184476 for the potential treatment of solid tumors. BMS-184476 participated in phase II clinical trials for patients with non-small-cell lung cancer, breast, and ovarian cancers. However, that development has been d...
Bristol-Myers Squibb developed BMS-188797 for the potential treatment of solid tumors. BMS-188797 causes G2/M cell cycle arrest and exhibits potent antiproliferative activity against human tumor cell. BMS-188797 in combination with cisplatin successf...